South Dakota Investment Council increased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 410.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 63,899 shares of the medical research company's stock after purchasing an additional 51,370 shares during the period. South Dakota Investment Council's holdings in IQVIA were worth $11,265,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in IQV. Private Advisor Group LLC lifted its holdings in shares of IQVIA by 11.6% in the 1st quarter. Private Advisor Group LLC now owns 5,435 shares of the medical research company's stock worth $958,000 after acquiring an additional 566 shares during the last quarter. Transce3nd LLC increased its holdings in IQVIA by 2,850.0% during the 1st quarter. Transce3nd LLC now owns 1,593 shares of the medical research company's stock valued at $280,000 after acquiring an additional 1,539 shares in the last quarter. Larson Financial Group LLC boosted its position in shares of IQVIA by 109.9% in the first quarter. Larson Financial Group LLC now owns 275 shares of the medical research company's stock worth $48,000 after acquiring an additional 144 shares during the last quarter. Wealthfront Advisers LLC boosted its position in shares of IQVIA by 7.4% in the first quarter. Wealthfront Advisers LLC now owns 4,310 shares of the medical research company's stock worth $760,000 after acquiring an additional 296 shares during the last quarter. Finally, First Business Financial Services Inc. lifted its position in IQVIA by 5.1% during the first quarter. First Business Financial Services Inc. now owns 10,309 shares of the medical research company's stock valued at $1,817,000 after buying an additional 503 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.
Analyst Ratings Changes
Several equities analysts have recently commented on IQV shares. Truist Financial lowered their price target on shares of IQVIA from $263.00 to $216.00 and set a "buy" rating for the company in a research report on Thursday, April 10th. Robert W. Baird reduced their price target on shares of IQVIA from $195.00 to $161.00 and set a "neutral" rating for the company in a research report on Wednesday, May 7th. JPMorgan Chase & Co. lowered their price target on IQVIA from $232.00 to $177.00 and set an "overweight" rating on the stock in a report on Monday, May 19th. Mizuho lowered their price objective on shares of IQVIA from $210.00 to $190.00 and set an "outperform" rating on the stock in a research note on Thursday, May 15th. Finally, HSBC cut IQVIA from a "buy" rating to a "hold" rating and cut their price objective for the company from $260.00 to $160.00 in a report on Friday, April 25th. Eight investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $222.45.
Read Our Latest Analysis on IQV
IQVIA Trading Down 1.5%
Shares of NYSE IQV traded down $2.37 during trading hours on Friday, reaching $160.88. The stock had a trading volume of 2,312,787 shares, compared to its average volume of 1,678,075. The company has a current ratio of 0.82, a quick ratio of 0.82 and a debt-to-equity ratio of 2.19. The business's fifty day moving average price is $152.90 and its two-hundred day moving average price is $170.67. The firm has a market cap of $27.83 billion, a price-to-earnings ratio of 21.92, a P/E/G ratio of 1.78 and a beta of 1.30. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $252.88.
IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.63 by $0.07. IQVIA had a return on equity of 29.16% and a net margin of 8.61%. The business had revenue of $3.83 billion for the quarter, compared to the consensus estimate of $3.77 billion. During the same period last year, the business posted $2.54 EPS. The business's revenue was up 2.5% compared to the same quarter last year. Analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.
About IQVIA
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Read More

Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.